Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al.
2011-10-20 • New England Journal of Medicine
2011-10-20 • New England Journal of Medicine
Tuberculosis remains an important cause of death among patients infected with the human immunodeficiency virus (HIV). Robust data are lacking with regard to the timing for the initiation...
Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, et al.
2014-08-01 • Clinical Infectious Diseases
2014-08-01 • Clinical Infectious Diseases
Shortening the interval between antituberculosis treatment onset and initiation of antiretroviral therapy (ART) reduces mortality in severely immunocompromised human immunodeficiency vir...
Borand L, Madec Y, Laureillard D, Chou M, Marcy O, et al.
2014-03-07 • PLOS One
2014-03-07 • PLOS One
OBJECTIVE To assess efavirenz plasma concentrations and their association with treatment efficacy and tolerance of efavirenz 600 mg daily in HIV-tuberculosis co-infected patients.
